SEO URLwww.firestrike.ai/deals/orexo-dexcel-pharma-usa-acquisition-2026
acquisitionAnnounced · Jan 7, 2026PharmaceuticalsSource · CredibleArticle · Factual
Dexcel Pharma USA acquires Orexo
David Najork · Founding Software Engineer
Published · Updated · 1 min read
Deal value
—
Target
Orexo
STO: ORX · Uppsala, Uppsala
Acquirer
Dexcel Pharma USA
Asset/Business Division Sale
Status
Completed
Dexcel Pharma USA agreed to acquire Orexo. Reported deal value: Undisclosed. Status: Completed. Sector: Pharmaceuticals. Target headquarters context: Uppsala, Uppsala, Sweden.
This page summarizes publicly available information about the transaction as of 2026-01-07. Figures and status may change as filings and press coverage update.
Dexcel Pharma USA is excited to announce the successful closing of an Asset Purchase Agreement with Orexo AB to acquire the U.S. rights to Zubsolv ® sublingual tablets and the associated commercial infrastructure
Deal timeline
Announced
Jan 7, 2026 · prnewswire.com
Additional milestones (proxy, vote, close) appear as filings and press updates are indexed.
Sector context
This transaction is classified in Pharmaceuticals. Figures and status may change as sources update.
Sources: prnewswire.com · Primary article · FireStrike proprietary index